499 related articles for article (PubMed ID: 25861829)
41. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
[TBL] [Abstract][Full Text] [Related]
42. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
43. Myelodysplastic syndrome.
Hofmann WK; Koeffler HP
Annu Rev Med; 2005; 56():1-16. PubMed ID: 15660498
[TBL] [Abstract][Full Text] [Related]
44. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
45. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
46. Myelodysplastic syndromes in the United States: an update for clinicians.
Troy JD; Atallah E; Geyer JT; Saber W
Ann Med; 2014 Aug; 46(5):283-9. PubMed ID: 24716735
[TBL] [Abstract][Full Text] [Related]
47. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
[TBL] [Abstract][Full Text] [Related]
48. Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia.
Layton DM; Mufti GJ
Blut; 1986 Dec; 53(6):423-36. PubMed ID: 3542084
[TBL] [Abstract][Full Text] [Related]
49. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Dill V; Kauschinger J; Hauch RT; Buschhorn L; Odinius TO; Müller-Thomas C; Mishra R; Kyncl MC; Schmidt B; Prodinger PM; Hempel D; Bellos F; Höllein A; Kern W; Haferlach T; Slotta-Huspenina J; Bassermann F; Peschel C; Götze KS; Waizenegger IC; Höckendorf U; Jost PJ; Jilg S
Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
[TBL] [Abstract][Full Text] [Related]
51. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
52. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
53. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
54. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
[TBL] [Abstract][Full Text] [Related]
55. Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group.
Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Tantiworawit A; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1075-e1083. PubMed ID: 36117042
[TBL] [Abstract][Full Text] [Related]
56. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
57. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
[TBL] [Abstract][Full Text] [Related]
58. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
[TBL] [Abstract][Full Text] [Related]
60. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
